Florence Maude Thomas Cancer Research Professor / Director, Myeloma Section / The University of Texas MD Anderson Cancer Center
Hematology
Dr. Robert Z. Orlowski, MD
|
|
Give Review
Robert Z. Orlowski practices Hematology. He went to medical school at Yale University School of Medicine. Yale University School of Medicine is a top medical university. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He has 3 awards "America's Top Doctors", "Top Doctors:SE Texas" and "America's Top Doctors for Cancer". Robert Orlowski is a published MD. He has 102 publications published. The most current publication "Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group." Robert Orlowski accepts Medicare.
Publications
- Crystal-storing histiocytosis: a clinicopathological study of 13 cases.
- Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple Myeloma.
- Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory Myeloma.
- Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
- Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
- The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediates Bortezomib Resistance in Multiple Myeloma.
- Mature adipocytes in bone marrow protect myeloma Cells against chemotherapy through autophagy activation.
- Long-term outcomes for newly-diagnosed multiple Myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, ...
- Efficacy of panobinostat and marizomib in Acute myeloid leukemia and bortezomib-resistant models.
- High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
- Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells.
- Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
- Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk Myeloma.
- Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem Cell transplantation for relapsed myeloma.
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple Myeloma.
- Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple Myeloma 1 year...
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Longitudinal analysis of patient-reported symptoms post-autologous stem Cell transplant and their relationship to inflammation in patients with multiple myeloma.
- A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refrac...
- A Bim-targeting strategy overcomes adaptive bortezomib-resistance in multiple Myeloma through a novel link between autophagy and apoptosis.
- Transmissible cytotoxicity of multiple myeloma Cells by cord blood-derived NK Cells is mediated by vesicle trafficking.
- Dynamic balance of multiple myeloma clonogenic side population Cell percentages controlled by environmental conditions.
- Targeting SQSTM1/p62 Induces Cargo-Loading Failure and Converts Autophagy to Apoptosis via NBK/Bik.
- The association of diabetes and anti-diabetic medications with clinical outcomes in multiple Myeloma.
- Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.
- Clinically silent clonal cytogenetic abnormalities arising in patients treated for lymphoid neoplasms.
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple Myeloma: SWOG S0434.
- Randomized, open label, phase 2 study of siltuximab (an anti IL 6 mAb) and bortezomib melphalan prednisone versus bortezomib-melphalan-prednisone in patients with newl...
- Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer in Vitro and in Vivo Via Exacerbating Unfolded Protein Responses.
- Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma Cells.
- Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation.
- Evidence of a role for CD44 and Cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.
- Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome.
- Osteoblastic niche supports the growth of quiescent multiple myeloma Cells.
- A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer.
- Mutation of NRAS but not KRAS significantly reduces Myeloma sensitivity to single-agent bortezomib therapy.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy.
- Clinical, genomic and imaging predictors of Myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
- Novel agents for multiple Myeloma to overcome resistance in phase III clinical trials.
- The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1.
- Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma.
- Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple Myeloma.
- Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
- Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma.
- Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk Myeloma: analysis of SWOG trial S0115.
- A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients w...
- Treatment outcomes in patients with relapsed and refractory multiple Myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
- Plasma Cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients wit...
- Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma.
- A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple Myeloma.
- p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction.
- An unusual case of aggressive systemic mastocytosis with associated refractory plasma Cell myeloma.
- Plasma cell Leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple Myeloma.
- Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase is Mediated by Point Mutations of p53, but can be Overcome with the p53 Targeting Agent RITA.
- The immunoproteasome as a target in hematologic malignancies.
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
- Constitutive activation of p38 MAPK in tumor Cells contributes to osteolytic bone lesions in multiple myeloma.
- Predictors of prolonged survival after allogeneic hematopoietic stem Cell transplantation for multiple myeloma.
- A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
- Cereblon expression is required for the anti-Myeloma activity of lenalidomide and pomalidomide.
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle Cell lymphoma.
- Feasibility of autologous hematopoietic stem Cell transplant in patients aged â¥70 years with multiple myeloma.
- In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 Against Multiple Myeloma Cells.
- Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple Myeloma patients.
- Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma Cells to lenalidomide.
- Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy.
- Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory Myeloma is associated w...
- Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple Myeloma: effects of adverse prognostic factors on outcome.
- Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma Cell growth in vitro and in vivo.
- Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic Breast cancer.
- Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
- A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
- Bortezomib and EGCG: no green tea for you?
- Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple Myeloma that overcomes resistance to conventional drugs and nonspecific pro...
- Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle Cell lymphoma.
- Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated Cell-cycle arrest and activation of autophagy.
- Proteasome inhibitors in Cancer therapy: lessons from the first decade.
- Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple Myeloma.
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple Myeloma.
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple Myeloma: combination th...
- Mitogen-activated protein kinase phosphatase-1 is a mediator of Breast cancer chemoresistance.
- Emerging data on the use of anthracyclines in combination with bortezomib in multiple Myeloma.
- A Phase I study of bortezomib plus irinotecan in patients with advanced solid Tumors.
- Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple Myeloma with bortezomib.
- Emerging role of novel combinations for induction therapy in multiple Myeloma.
- A practical update on the use of bortezomib in the management of multiple Myeloma.
- Initial therapy of multiple myeloma patients who are not candidates for stem Cell transplantation.
- The proteasome and proteasome inhibitors in Cancer therapy.
- Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
- Proteasome inhibitors in Cancer therapy.
- The ubiquitin proteasome pathway from bench to bedside.
- Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
- Bortezomib in combination with other therapies for the treatment of multiple Myeloma.
- The proteasome as a target for Cancer therapy.
- Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.
- A phase 2 study of bortezomib in relapsed, refractory Myeloma.
- Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.
- Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous Leukemia.
- Treatment of Multiple Myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Schools
Yale Univ Sch Of Med
Barnes HospWash University
Johns Hopkins University
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
Education
-
Johns Hopkins University -
Washington University - Barnes-Jewish Hospital -
Yale University School of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1336209956 | |
| NPPES Provider LastName | ORLOWSKI | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 770304000 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 611.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 57.0 | |
| Percent Opioid Claims | 9.33 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1336209956 |
| Last Name Of The Provider | ORLOWSKI |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
Dr. Alex P. Nguyen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert S. Benjamin, MD |
|
|
Dr. Navid Sadeghi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erminia Massarelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanam Loghavi, MD |
|
|
Dr. Chung C. Lee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer Wheler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaffer A. Ajani, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Andreeff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vivian T. Yin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Gloria Anyadike, FNP |